MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 585167 | Name: Betaxolol
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Betaxolol is a cardioselective beta-1-adrenergic antagonist with no partial agonist activity.

Chemical Structure

Betaxolol
CAS#63659-18-7 (free base)

Theoretical Analysis

MedKoo Cat#: 585167

Name: Betaxolol

CAS#: 63659-18-7 (free base)

Chemical Formula: C18H29NO3

Exact Mass: 307.2147

Molecular Weight: 307.43

Elemental Analysis: C, 70.32; H, 9.51; N, 4.56; O, 15.61

Price and Availability

Size Price Availability Quantity
50mg USD 350.00 2 Weeks
100mg USD 600.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
63659-18-7 (free base) 63659-19-8 (HCl) 93221-48-8 (S-isomer free base) 116209-55-3 (S-isomer HCl)
Synonym
Betaxolol; SL 75212; SL75212; SL-75212; Betaxololum; Betoptic; Kerlone
IUPAC/Chemical Name
2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-
InChi Key
NWIUTZDMDHAVTP-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3
SMILES Code
OC(CNC(C)C)COC1=CC=C(CCOCC2CC2)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 307.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002 Oct;120(10):1268-79. PubMed PMID: 12365904. 2: Hering D, Kucharska W, Chrostowska M, Narkiewicz K. Age-dependent sympathetic neural responses to ß(1) selective beta-blockade in untreated hypertension-related tachycardia. Blood Press. 2018 Jun;27(3):158-165. doi: 10.1080/08037051.2018.1423543. Epub 2018 Jan 8. PubMed PMID: 29308931. 3: Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E; Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003 Jan;121(1):48-56. PubMed PMID: 12523884. 4: Leske MC, Heijl A, Hyman L, Bengtsson B. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999 Nov;106(11):2144-53. PubMed PMID: 10571351. 5: Zhu Q, Wei Y, Li C, Mao S. Inner layer-embedded contact lenses for ion-triggered controlled drug delivery. Mater Sci Eng C Mater Biol Appl. 2018 Dec 1;93:36-48. doi: 10.1016/j.msec.2018.07.065. Epub 2018 Jul 24. PubMed PMID: 30274068. 6: Goldberg I. Betaxolol. Aust N Z J Ophthalmol. 1989 Feb;17(1):9-13. Review. PubMed PMID: 2569884. 7: Xu K, Campbell EL, Gill SS, Nesdole R, Campbell RJ. Impact of Combination Glaucoma Therapies on β-Blocker Exposure. J Glaucoma. 2017 Feb;26(2):e107-e109. doi: 10.1097/IJG.0000000000000500. PubMed PMID: 28059862. 8: Brooks AM, Gillies WE. Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging. 1992 May-Jun;2(3):208-21. Review. PubMed PMID: 1351412. 9: El-Kimary EI, Ragab MAA. Box-Behnken response surface modeling assisted enantiomeric resolution of some racemic β-blockers using HPTLC and β-cyclodextrin as chiral mobile phase additive: Application to check the enantiomeric purity of betaxolol. Chirality. 2018 Nov;30(11):1195-1205. doi: 10.1002/chir.23012. Epub 2018 Sep 7. PubMed PMID: 30193408. 10: Li J, Tian S, Tao Q, Zhao Y, Gui R, Yang F, Zang L, Chen Y, Ping Q, Hou D. Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma. Int J Nanomedicine. 2018 Jul 10;13:3975-3987. doi: 10.2147/IJN.S162306. eCollection 2018. PubMed PMID: 30022821; PubMed Central PMCID: PMC6045908. 11: Huang Y, Tao Q, Hou D, Hu S, Tian S, Chen Y, Gui R, Yang L, Wang Y. A novel ion-exchange carrier based upon liposome-encapsulated montmorillonite for ophthalmic delivery of betaxolol hydrochloride. Int J Nanomedicine. 2017 Mar 2;12:1731-1745. doi: 10.2147/IJN.S122747. eCollection 2017. PubMed PMID: 28280338; PubMed Central PMCID: PMC5340245. 12: Okutucu M, Fındık H, Arslan MG. Direct and crossover effects of brinzolamide, betaxolol, and latanoprost on choroidal thickness. Cutan Ocul Toxicol. 2019 Jun;38(2):196-200. doi: 10.1080/15569527.2019.1575390. Epub 2019 Mar 1. PubMed PMID: 30719935. 13: Tian S, Li J, Tao Q, Zhao Y, Lv Z, Yang F, Duan H, Chen Y, Zhou Q, Hou D. Controlled drug delivery for glaucoma therapy using montmorillonite/Eudragit microspheres as an ion-exchange carrier. Int J Nanomedicine. 2018 Jan 12;13:415-428. doi: 10.2147/IJN.S146346. eCollection 2018. PubMed PMID: 29391798; PubMed Central PMCID: PMC5769559. 14: Zhu Q, Cheng H, Huo Y, Mao S. Sustained ophthalmic delivery of highly soluble drug using pH-triggered inner layer-embedded contact lens. Int J Pharm. 2018 Jun 10;544(1):100-111. doi: 10.1016/j.ijpharm.2018.04.004. Epub 2018 Apr 5. PubMed PMID: 29627356. 15: Örnek N, Oğurel R, Örnek K. Congenital hypothyroidism in Rieger Syndrome. Ophthalmic Genet. 2016;37(1):86-8. doi: 10.3109/13816810.2014.902079. Epub 2014 Mar 25. PubMed PMID: 24666291. 16: Figulla HR, Krzeminska-Pakula M, Wrabec K, Chochola J, Kalmbach C, Fridl P. Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial). Int J Cardiol. 2006 Nov 10;113(2):153-60. Epub 2005 Sep 12. PubMed PMID: 16157399. 17: Buckley MM, Goa KL, Clissold SP. Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension. Drugs. 1990 Jul;40(1):75-90. Review. PubMed PMID: 2202584. 18: Swartz CM. Betaxolol in anxiety disorders. Ann Clin Psychiatry. 1998 Mar;10(1):9-14. PubMed PMID: 9622045. 19: Šrámková I, Chocholouš P, Sklenářová H, Šatínský D. On-line coupling of Micro-Extraction by Packed Sorbent with Sequential Injection Chromatography system for direct extraction and determination of betaxolol in human urine. Talanta. 2015 Oct 1;143:132-137. doi: 10.1016/j.talanta.2015.05.048. Epub 2015 May 22. PubMed PMID: 26078140. 20: Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z; EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007 Nov;114(11):1965-72. Epub 2007 Jul 12. PubMed PMID: 17628686.